MG
NGNE icon

Michael Gelband’s Neurogene NGNE Stock Holding History

Michael Gelband’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,119
Closed -$600K – 1914
2025
Q4 		$600K Sell
29,119
-3,402
-10% -$84.7K ﹤0.01% 1146
2025
Q3 		$564K Buy
+32,521
New +$653K 0.01% 1142
2024
Q2 		– Sell
-6,382
Closed -$325K – 1823
2024
Q1 		$325K Sell
6,382
-13,924
-69% -$465K ﹤0.01% 1243
2023
Q4 		$394K Buy
+20,306
New +$291K ﹤0.01% 1102
2022
Q2 		– Sell
-774
Closed -$29K – 2269
2022
Q1 		$29K Buy
+774
New +$45.2K ﹤0.01% 2094
2021
Q4 		– Sell
-570
Closed -$82K – 2459
2021
Q3 		$82K Sell
570
-323
-36% -$49.5K ﹤0.01% 1927
2021
Q2 		$165K Buy
+893
New +$198K ﹤0.01% 2039
2020
Q2 		– Sell
-4,158
Closed -$946K – 1939
2020
Q1 		$946K Sell
4,158
-2,103
-34% -$433K 0.05% 322
2019
Q4 		$1.54M Buy
+6,261
New +$624K 0.03% 410

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Michael Gelband's NGNE Position: Q1 2026 in Review

Michael Gelband sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 29,119 shares — an estimated $600K sold.

Michael Gelband first reported a position in NGNE in Q4 2019 and held it in 9 quarters. The position peaked at $1.54M in Q4 2019. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Michael Gelband reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 29,119 Neurogene shares in Q1 2026, an estimated $600K.
  • Michael Gelband first reported a position in Neurogene in Q4 2019 and held it in 9 quarters.
  • Michael Gelband's Neurogene position peaked at $1.54M in Q4 2019.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.